Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.47
0.132.43%
At close: Apr 22, 5:00 PM EST
$5.45
-0.02-0.37%
After Hours: 7:27 PM EST
Opus Genetics Inc Analyst Ratings
IRDNASDAQ
Opus Genetics Analyst Ratings and Price Targets | NASDAQ:IRD | Benzinga
Opus Genetics Inc has a consensus price target of $9.18 based on the ratings of 11 analysts. The high is $15 issued by Cantor Fitzgerald on March 30, 2026. The low is $5 issued by LUCID CAPITAL MARKETS on June 17, 2025. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Oppenheimer, and Wedbush on March 30, 2026, March 16, 2026, and March 12, 2026, respectively. With an average price target of $11.67 between Cantor Fitzgerald, Oppenheimer, and Wedbush, there's an implied 114.07% upside for Opus Genetics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Oppenheimer
Wedbush
Chardan Capital
BTIG
1calculated from analyst ratings
Analyst Ratings for Opus Genetics
Loading calendar...
FAQ
What is the target price for Opus Genetics (IRD) stock?
The latest price target for Opus Genetics (NASDAQ:IRD) was reported by Cantor Fitzgerald on March 30, 2026. The analyst firm set a price target for $15.00 expecting IRD to rise to within 12 months (a possible 175.23% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Opus Genetics (IRD)?
The latest analyst rating for Opus Genetics (NASDAQ:IRD) was provided by Cantor Fitzgerald, and Opus Genetics initiated their overweight rating.
When was the last upgrade for Opus Genetics (IRD)?
There is no last upgrade for Opus Genetics
When was the last downgrade for Opus Genetics (IRD)?
There is no last downgrade for Opus Genetics.
When is the next analyst rating going to be posted or updated for Opus Genetics (IRD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Opus Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Opus Genetics was filed on March 30, 2026 so you should expect the next rating to be made available sometime around March 30, 2027.
Is the Analyst Rating Opus Genetics (IRD) correct?
While ratings are subjective and will change, the latest Opus Genetics (IRD) rating was a initiated with a price target of $0.00 to $15.00. The current price Opus Genetics (IRD) is trading at is $5.45, which is within the analyst’s predicted range.
